1. Skip to Menu
  2. Skip to Content
  3. Skip to Footer


Updated advice on use of high-dose ibuprofen

Please see the press release from the European Medicines Agency on Ibuprofen. The full press release is available here.

Review confirms small cardiovascular risk with daily doses at or above 2,400 mg

The CMDh1 has endorsed by consensus updated advice on the use of high-dose ibuprofen. This follows a review carried out by EMA’s Pharmacovigilance Risk Assessment Committee (PRAC), which confirmed a small increased risk of cardiovascular problems, such as heart attacks and strokes, in patients taking high doses of ibuprofen (at or above 2,400 mg per day).

The review clarifies that the risk with high-dose ibuprofen is similar to the risk seen with some other non-steroidal anti-inflammatory drugs (NSAIDs), including COX-2 inhibitors and diclofenac.

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Cookie Use Page.

I accept cookies from this site.